# Infinity Pharmaceuticals

Source: https://onco.cc/companies/infinity-pharmaceuticals/  
OnCo record `infinity-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Infinity was the Cambridge biotech that discovered duvelisib, the PI3K-delta/gamma inhibitor later approved for chronic lymphocytic leukaemia, before licensing it out and turning to eganelisib; it filed for bankruptcy in 2023.

## Summary

Infinity Pharmaceuticals, founded in 2001 in Cambridge, Massachusetts, developed duvelisib (IPI-145) through the phase 3 DUO trial in relapsed chronic lymphocytic leukaemia before licensing it to Verastem, which won approval in 2018. Its later PI3K-gamma inhibitor eganelisib reached phase 2 in combination with checkpoint inhibitors, and the company filed for bankruptcy in 2023. Its trials remain on ClinicalTrials.gov under Infinity as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Infinity Pharmaceuticals, Inc.; Infinity
- Tags: ctgov-sponsor
- HQ: Cambridge, MA
- Type: biotech
- Website: http://www.infi.com

## Sources

- Official website: http://www.infi.com
- ClinicalTrials.gov: trials led by Infinity Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Infinity%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30296176

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Duvelisib](https://onco.cc/drugs/duvelisib/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/infinity-pharmaceuticals.json